ICER Draft Evidence Report on peanut allergy therapies

10 April 2019

The Institute for Clinical and Economic Review (ICER) yesterday released a Draft Evidence Report assessing the clinical effectiveness and value of two new technologies to induce immune tolerance — Viaskin Peanut, from French allergy specialist DBV Technologies (Euronext Paris: DBV)) and AR101 from US biotech firm Aimmune Therapeutics (Nasdaq: AIMT) — as well as non-commercialized oral immunotherapy (OIT).

This draft report, wich questions the cost effectiveness of the products, will be open to public comment until 5pm ET on May 8, 2019. Based on stakeholder feedback, the ICER may revise key assumptions and findings for its Evidence Report, which will be published on May 28, 2019.

The Evidence Report will be subject to deliberation during a public meeting of the California Technology Assessment Forum ( CTAF), one of ICER’s three independent evidence appraisal committees, on June 11, 2019.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK